

POSTER PRESENTATION

Open Access

# Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)

Dung T Le<sup>1\*</sup>, Todd S Crocenzi<sup>2</sup>, Jennifer N Urum<sup>3</sup>, Eric R Lutz<sup>1</sup>, Daniel A Laheru<sup>3</sup>, Elizabeth A Sugar<sup>4</sup>, Robert H Vonderheide<sup>5</sup>, George A Fisher<sup>6</sup>, Andrew H Ko<sup>7</sup>, Aimee L Murphy<sup>8</sup>, Katherine McDougall<sup>9</sup>, Sandy Ferber<sup>10</sup>, Dirk G Brockstedt<sup>11</sup>, Elizabeth M Jaffee<sup>1</sup>

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

National Harbor, MD, USA. 4-8 November 2015

## Background

A heterologous prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing promise in patients with pancreatic adenocarcinoma (PDA) (Le, JCO 2015). Furthermore, blockade of the immune checkpoint programmed death-1 (PD-1) is active in some cancers. Combinatorial strategies aimed at priming tumor antigen-specific T cells while simultaneously blocking negative checkpoints may be necessary to improve outcomes in PDA. GVAX is composed of allogeneic pancreatic cancer cells modified to express GM-CSF and induces a broad response against multiple tumor antigens. GVAX is given with low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated *Listeria monocytogenes* engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and is unique in its capacity to stimulate both innate and adaptive immunity by activating T cells and NK cells. Nivolumab is an antibody against PD-1.

## Methods

This is a Phase II study comparing CY/GVAX and CRS-207 with or without nivolumab in subjects with PDA who

failed only one chemotherapy regimen for metastatic disease. Subjects are randomized in a 1:1 ratio to receive either 2 doses of CY/nivolumab/GVAX and 4 doses of nivolumab/CRS-207 (Arm A) or 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm B). The primary objective is to compare OS between Arms A and B. Secondary/exploratory objectives include: assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of *Lm*- and mesothelin-specific T cell and other immunological responses with OS, progression-free survival and best overall response.

## Authors' details

<sup>1</sup>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. <sup>2</sup>Providence Cancer Center, Portland, OR, USA. <sup>3</sup>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. <sup>4</sup>Departments of Biostatistics and Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. <sup>5</sup>University of Pennsylvania, Baltimore, MD, USA. <sup>6</sup>Stanford University School of Medicine, Stanford, CA, USA. <sup>7</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. <sup>8</sup>Aduro BioTech, Inc., Berkeley, CA, USA. <sup>9</sup>Aduro Biotech, Berkeley, CA, USA. <sup>10</sup>Array Biostatistics LLC, Evanston, IL, USA. <sup>11</sup>Aduro Biotech, Inc., Berkeley, CA, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P155

Cite this article as: Le et al.: Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR). *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P155.

<sup>1</sup>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

Full list of author information is available at the end of the article